Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

SGLT2 inhibitors carry no excess risk of amputation

12 Jun 2020

Neither canagliflozin nor other sodium glucose co-transporter-2 (SGLT2) inhibitors contribute to an increased risk of amputation among patients with diabetes mellitus, as reported in a recent study.

Researchers performed a systematic review and meta-analysis of randomized controlled trials evaluating the risk of amputation in relation to the use of SGLT2 inhibitors vs non-SGLT2 inhibitors or placebo in patients with diabetes.

The meta-analysis included five trials involving a total of 39,067 patients with diabetes mellitus, among whom 21,395 were on SGLT2 inhibitors. The proportion of those who had had limb amputation varied between 0.36 percent and 3.18 percent in the SGLT2 group and between 0 percent and 2.87 percent in the control group. Follow-up duration ranged from 24 weeks to 4.2 years.

Pooled data showed no significant difference in the risk of amputation among patients in the SGLT2 and control groups (odds ratio, 1.31, 95 percent confidence interval [CI], 0.92–1.87; I2, 75 percent). Results for the subgroup analysis were consistent, indicating that canagliflozin, empagliflozin, and dapagliflozin did not contribute to a risk increase.

Assessed using the Cochrane tool, the risk of bias among the studies was low because they reported adequate random sequence generation and allocation concealment.

However, the researchers highlighted a need for additional studies, as types of amputations could be heterogeneous and the results may be skewed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.